Molecular biomarkers in multiple sclerosis

por Ziemssen, Tjalf, Akgün, Katja, Brück, Wolfgang
Publicado 2019

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies

por Akgün, Katja, Essner, Ute, Seydel, Cordula, Ziemssen, Tjalf
Publicado 2019

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration

por Sehr, Tony, Akgün, Katja, Haase, Rocco, Ziemssen, Tjalf
Publicado 2020

Should We Use Clinical Tools to Identify Disease Progression?

por Inojosa, Hernan, Proschmann, Undine, Akgün, Katja, Ziemssen, Tjalf
Publicado 2021

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

por Proschmann, Undine, Inojosa, Hernan, Akgün, Katja, Ziemssen, Tjalf
Publicado 2021

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

por Woopen, Christina, Schleußner, Katharina, Akgün, Katja, Ziemssen, Tjalf
Publicado 2021

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects

por Fischer, Stefanie, Proschmann, Undine, Akgün, Katja, Ziemssen, Tjalf
Publicado 2021

The need for a strategic therapeutic approach: multiple sclerosis in check

por Inojosa, Hernan, Proschmann, Undine, Akgün, Katja, Ziemssen, Tjalf
Publicado 2022

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses

por Woopen, Christina, Konofalska, Urszula, Akgün, Katja, Ziemssen, Tjalf
Publicado 2022

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review

por Constantinescu, Victor, Haase, Rocco, Akgün, Katja, Ziemssen, Tjalf
Publicado 2022

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

por Akgün, Katja, Behrens, Johanna, Schriefer, Dirk, Ziemssen, Tjalf
Publicado 2022

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients

por Nötzel, Martin, Werder, Luise Ina, Ziemssen, Tjalf, Akgün, Katja
Publicado 2022

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients

por Kaufmann, Maxi, Haase, Rocco, Proschmann, Undine, Ziemssen, Tjalf, Akgün, Katja
Publicado 2018

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

por Kaufmann, Maxi, Haase, Rocco, Proschmann, Undine, Ziemssen, Tjalf, Akgün, Katja
Publicado 2018

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis

por Akgün, Katja, Blankenburg, Judith, Marggraf, Michaela, Haase, Rocco, Ziemssen, Tjalf
Publicado 2020

Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis

por Jin, Mengmeng, Günther, Rene, Akgün, Katja, Hermann, Andreas, Ziemssen, Tjalf
Publicado 2020

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation

por Proschmann, Undine, Haase, Rocco, Inojosa, Hernan, Akgün, Katja, Ziemssen, Tjalf
Publicado 2021

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis

por Akgün, Katja, Metz, Imke, Kitzler, Hagen H., Brück, Wolfgang, Ziemssen, Tjalf
Publicado 2018

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

por Inojosa, Hernan, Eisele, Judith, Proschmann, Undine, Zeissig, Sebastian, Akgün, Katja, Ziemssen, Tjalf
Publicado 2020

Digital Twins for Multiple Sclerosis

por Voigt, Isabel, Inojosa, Hernan, Dillenseger, Anja, Haase, Rocco, Akgün, Katja, Ziemssen, Tjalf
Publicado 2021